EUVIMEDEUVIMED entdecken
Systematische ÜbersichtLeitlinieOpen Access · CC BY 4.0

Guideline of guidelines: a critical appraisal of the evidence for PSA retesting intervals

Kiana K Collins iD, Pradeep S Virdee, Nia Roberts, Jason L Oke, Brian D Nicholson iD

BJU International · 2025

DOI: 10.1111/bju.16809 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift BJU International, 2025. Verfasst von Kiana K Collins und 4 weiteren Autor:innen. Beteiligte Einrichtung: Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Neoplasms, Practice Guidelines as Topic, Early Detection of Cancer. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research, Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To summarise the recommendations for prostate‐specific antigen (PSA) retesting intervals and to evaluate the evidence cited by each guideline by conducting a systematic review of clinical practice guidelines.

Methods

We searched PubMed and the Turning Research into Practice (TRIP) database for guidelines written in English and developed or updated in 2013–2024. Guideline quality assessment was performed using the AGREE II tool. We narratively synthesised results.

Results

Eleven guidelines were included. Ten (91%) recommended PSA retesting intervals of approximately 2 to 4 years. A total of 37 studies were referenced as evidence for the recommended intervals across the 11 guidelines. Five of these studies (14%) had the objective of determining PSA retesting intervals. Fourteen studies (38%) analysed single PSA test results. Five guideline recommendations partially aligned with the evidence referenced and five did not align.

Conclusions

Generally, for asymptomatic patients aged ≥50 years with PSA levels between 1 and 3 ng/mL, most guidance recommended a retesting interval of 2–4 years, with the possibility to extend the interval to 4–10 years for patients with a PSA value

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostate-Specific AntigenProstatic NeoplasmsPractice Guidelines as TopicEarly Detection of CancerHumansMaleTime Factors

Stichwörter der Autor:innen

AGREE IIintervalsprostate cancerprostate‐specific antigensystematic review

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
  • Bodleian Health Care Libraries, Oxford, UK.

ORCID-Profile: Kiana K Collins, Brian D Nicholson

Förderung

  • National Institute for Health and Care Research
  • Cancer Research UK

Zitieren

APA

Collins, K. K., Virdee, P. S., Roberts, N., Oke, J. L., & Nicholson, B. D. (2025). Guideline of guidelines: a critical appraisal of the evidence for PSA retesting intervals. BJU International. https://doi.org/10.1111/bju.16809

Vancouver

Collins KK, Virdee PS, Roberts N, Oke JL, Nicholson BD. Guideline of guidelines: a critical appraisal of the evidence for PSA retesting intervals. BJU International. 2025. doi:10.1111/bju.16809

BibTeX
@article{Collins2025,
  author = {Collins, Kiana K and Virdee, Pradeep S and Roberts, Nia and Oke, Jason L and Nicholson, Brian D},
  title = {Guideline of guidelines: a critical appraisal of the evidence for PSA retesting intervals},
  journal = {BJU International},
  year = {2025},
  doi = {10.1111/bju.16809}
}
Kostenlos starten →